Current status of inherited pancreatic cancer.
Familial pancreatic cancer
Hereditary syndromes
Mutation
Pancreatic cancer
Screening
Journal
Hereditary cancer in clinical practice
ISSN: 1731-2302
Titre abrégé: Hered Cancer Clin Pract
Pays: Poland
ID NLM: 101231179
Informations de publication
Date de publication:
27 Jun 2022
27 Jun 2022
Historique:
received:
14
06
2021
accepted:
30
03
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
It is estimated that about 10% of pancreatic cancer cases have a genetic background. People with a familial predisposition to pancreatic cancer can be divided into 2 groups. The first is termed hereditary pancreatic cancer, which occurs in individuals with a known hereditary cancer syndrome caused by germline single gene mutations (e.g., BRCA1/2, CDKN2A). The second is considered as familial pancreatic cancer, which is associated with several genetic factors responsible for the more common development of pancreatic cancer in certain families, but the precise single gene mutation has not been found. This review summarizes the current state of knowledge regarding the risk of pancreatic cancer development in hereditary pancreatic cancer and familial pancreatic cancer patients. Furthermore, it gathers the latest recommendations from the three major organizations dealing with the prevention of pancreatic cancer in high-risk groups and explores recent guidelines of scientific societies on screening for pancreatic cancers in individuals at risk for hereditary or familial pancreatic cancer. In order to improve patients' outcomes, authors of current guidelines recommend early and intensive screening in patients with pancreatic cancer resulting from genetic background. The screening should be performed in excellence centers. The scope, extent and cost-effectiveness of such interventions requires further studies.
Sections du résumé
BACKGROUND
BACKGROUND
It is estimated that about 10% of pancreatic cancer cases have a genetic background. People with a familial predisposition to pancreatic cancer can be divided into 2 groups. The first is termed hereditary pancreatic cancer, which occurs in individuals with a known hereditary cancer syndrome caused by germline single gene mutations (e.g., BRCA1/2, CDKN2A). The second is considered as familial pancreatic cancer, which is associated with several genetic factors responsible for the more common development of pancreatic cancer in certain families, but the precise single gene mutation has not been found.
AIM
OBJECTIVE
This review summarizes the current state of knowledge regarding the risk of pancreatic cancer development in hereditary pancreatic cancer and familial pancreatic cancer patients. Furthermore, it gathers the latest recommendations from the three major organizations dealing with the prevention of pancreatic cancer in high-risk groups and explores recent guidelines of scientific societies on screening for pancreatic cancers in individuals at risk for hereditary or familial pancreatic cancer.
CONCLUSIONS
CONCLUSIONS
In order to improve patients' outcomes, authors of current guidelines recommend early and intensive screening in patients with pancreatic cancer resulting from genetic background. The screening should be performed in excellence centers. The scope, extent and cost-effectiveness of such interventions requires further studies.
Identifiants
pubmed: 35761384
doi: 10.1186/s13053-022-00224-2
pii: 10.1186/s13053-022-00224-2
pmc: PMC9235234
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
26Informations de copyright
© 2022. The Author(s).
Références
J Med Genet. 2010 Jun;47(6):421-8
pubmed: 20522432
Fam Cancer. 2008;7(1):103-12
pubmed: 17992582
Fam Cancer. 2011 Jun;10(2):323-30
pubmed: 21207249
Clin Genet. 2014 Aug;86(2):190-3
pubmed: 24032978
Gut. 2007 May;56(5):601-5
pubmed: 16973716
Trends Biochem Sci. 2019 Mar;44(3):226-240
pubmed: 30638972
J Gastrointest Surg. 2009 Aug;13(8):1487-94
pubmed: 19459017
Breast. 2017 Feb;31:224-232
pubmed: 27931006
Genet Med. 2015 Jul;17(7):569-77
pubmed: 25356972
Nat Genet. 2014 Sep;46(9):994-1000
pubmed: 25086665
Med Clin North Am. 2000 May;84(3):565-73
pubmed: 10872414
Br J Cancer. 2012 Dec 4;107(12):2005-9
pubmed: 23099806
Fam Cancer. 2011 Jun;10(2):225-31
pubmed: 21365267
J Clin Oncol. 2007 Apr 10;25(11):1417-22
pubmed: 17416862
Gastroenterology. 2020 Jul;159(1):358-362
pubmed: 32416142
Pancreas. 2018 Oct;47(9):1078-1086
pubmed: 30134356
Pol Arch Med Wewn. 2008 Nov;118(11):645-9
pubmed: 19140568
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
J Clin Med. 2021 Jan 27;10(3):
pubmed: 33513864
J Natl Cancer Inst. 2010 Jan 20;102(2):119-26
pubmed: 20068195
Cancer Med. 2020 Sep;9(18):6843-6853
pubmed: 32716590
Cancer Manag Res. 2020 Jan 31;12:743-758
pubmed: 32099470
Cancer Res. 2004 Apr 1;64(7):2634-8
pubmed: 15059921
Hum Genet. 2008 Oct;124(3):271-8
pubmed: 18762988
Nat Commun. 2018 Feb 8;9(1):556
pubmed: 29422604
Am J Gastroenterol. 2018 Sep;113(9):1376
pubmed: 30018304
Pancreatology. 2021 Aug;21(5):848-853
pubmed: 34140232
Cancer Lett. 2016 Oct 10;381(1):269-77
pubmed: 27461582
Dtsch Arztebl Int. 2021 Mar 05;118(Forthcoming):
pubmed: 33531114
Oncotarget. 2017 Apr 20;8(42):73240-73257
pubmed: 29069866
Int J Cancer. 2016 Aug 1;139(3):601-6
pubmed: 27038244
Pancreatology. 2005;5 Suppl 1:1-15
pubmed: 15942268
Nat Genet. 2010 Mar;42(3):224-8
pubmed: 20101243
Mol Cancer Ther. 2019 Nov;18(11):1899-1908
pubmed: 31676541
Fam Cancer. 2016 Jul;15(3):487-91
pubmed: 26892865
Cancer Res Treat. 2017 Apr;49(2):430-436
pubmed: 27488870
Clin Gastroenterol Hepatol. 2004 Mar;2(3):252-61
pubmed: 15017610
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):698-710
pubmed: 32135127
Int J Colorectal Dis. 2000 Feb;15(1):35-8
pubmed: 10766089
Gastrointest Endosc Clin N Am. 2018 Oct;28(4):587-603
pubmed: 30241646
J Clin Oncol. 2020 May 1;38(13):1442-1454
pubmed: 32073954
Nature. 2000 Nov 23;408(6811):429-32
pubmed: 11100717
Endoscopy. 2009 Jun;41(6):504-9
pubmed: 19533554
Pancreas. 2011 Aug;40(6):974-8
pubmed: 21487321
Cold Spring Harb Perspect Med. 2017 Apr 3;7(4):
pubmed: 28270529
Gastrointest Cancer Res. 2011 Jan;4(1):24-8
pubmed: 21464868
Nat Commun. 2018 Sep 11;9(1):3688
pubmed: 30206226
Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1238-1245
pubmed: 31015203
Gut. 2021 Mar;70(3):606-617
pubmed: 32855305
Gut. 2010 Jul;59(7):975-86
pubmed: 20581245
Clin Genet. 2017 Dec;92(6):649-653
pubmed: 28369810
Arch Pathol Lab Med. 2019 Nov;143(11):1382-1398
pubmed: 31070935
Nat Commun. 2020 Jun 24;11(1):3175
pubmed: 32581250
Gut. 1993 Oct;34(10):1394-6
pubmed: 8244108
Fam Cancer. 2004;3(1):1-10
pubmed: 15131399
Dig Liver Dis. 2013 Feb;45(2):95-9
pubmed: 23206934
Int J Cancer. 2000 Sep 15;87(6):809-11
pubmed: 10956390
Fam Cancer. 2022 Apr;21(2):211-227
pubmed: 34125377
Ann Transl Med. 2015 Sep;3(15):210
pubmed: 26488006
Curr Treat Options Gastroenterol. 2017 Dec;15(4):562-575
pubmed: 28879469
J Am Coll Surg. 2014 Apr;218(4):530-43
pubmed: 24655839
N Engl J Med. 2018 Aug 23;379(8):764-773
pubmed: 30134129
Cancer Res. 2006 Oct 15;66(20):9818-28
pubmed: 17047042
J Gastrointest Surg. 2013 May;17(5):847-56; discussion 856-7
pubmed: 23435738
World J Gastroenterol. 2020 Jun 14;26(22):3076-3086
pubmed: 32587449
Dig Liver Dis. 2020 Oct;52(10):1126-1130
pubmed: 32819857
Gastrointest Endosc Clin N Am. 2022 Jan;32(1):45-58
pubmed: 34798986
Cancer Biol Ther. 2009 Jan;8(2):131-5
pubmed: 19029836
Pancreatology. 2021 Apr;21(3):544-549
pubmed: 33612442
Gut. 2006 Feb;55(2):252-8
pubmed: 15972300
Gut. 2020 Jan;69(1):7-17
pubmed: 31672839
Nihon Shokakibyo Gakkai Zasshi. 2019;116(12):1015-1021
pubmed: 31827041
Cancer Prev Res (Phila). 2021 Apr;14(4):433-440
pubmed: 33509806
Colorectal Dis. 2012 Aug;14(8):947-52
pubmed: 21973191
Int J Cancer. 2021 Apr 1;148(7):1658-1664
pubmed: 33300603
Hum Mutat. 2011 Apr;32(4):407-14
pubmed: 21309036
Semin Cancer Biol. 2022 Feb;79:105-131
pubmed: 32818625
J Gastroenterol. 2018 Jan;53(1):152-160
pubmed: 28861620
J Cancer. 2017 Oct 11;8(18):3667-3674
pubmed: 29151953
Eur J Hum Genet. 2018 Aug;26(8):1227-1229
pubmed: 29769629
Dig Liver Dis. 2013 Jul;45(7):606-11
pubmed: 23415580
Cancer Biol Ther. 2010 Sep 1;10(5):430-7
pubmed: 20657174
Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):999-1008
pubmed: 32321713
Gastroenterology. 2018 Sep;155(3):740-751.e2
pubmed: 29803839
Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):803-11
pubmed: 23456555
EBioMedicine. 2019 Oct;48:581-591
pubmed: 31628023
Gut. 2007 Oct;56(10):1460-9
pubmed: 17872573
Eur J Epidemiol. 2020 Oct;35(10):975-986
pubmed: 31564045
Gastrointest Endosc. 2021 Feb;93(2):457-466
pubmed: 32535190
Oncol Res Treat. 2018;41(10):611-618
pubmed: 30269130
World J Gastrointest Oncol. 2019 Feb 15;11(2):102-116
pubmed: 30788038